Medicines Co. still fighting for Angiomax patent

In spite of a third rejection from the U.S. Patent Office, Medicines Co. CEO Clive Meanwell says he will pursue all options to extend its exclusive rights to the anticoagulant drug Angiomax that accounts for 95 percent of the company's revenue. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.